Segment and Related Information (Tables)

3 Months Ended

Sep. 30, 2014

Segment Revenue and Operating Income (Loss)

Segment revenue and operating income (loss) were as follows during the periods presented:


	Molecular		Pharmaceutical &
(In thousands)	diagnostics		clinical services			Research			Total
Three months ended September 30, 2014:
Revenue	$	164,507		4,330			—		$	168,837
Depreciation and amortization		4,978		449			527			5,954
Segment operating income (loss)		45,083		(1,782	)		(17,381	)		25,920
Three months ended September 30, 2013:
Revenue	$	192,987		9,480			—		$	202,467
Depreciation and amortization		1,362		500			510			2,372
Segment operating income (loss)		97,746		1,838			(16,680	)		82,904


	Three months ended
	September 30,
(In thousands)	2014			2013
Total operating income for reportable segments	$	25,920		$	82,904
Interest income		55			1,362
Other		(98	)		(439	)
Income tax provision		9,895			28,362

Net income	$	15,982		$	55,465

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details